Do analysts recommend NLTX or MLTX?

MoonLake Immunotherapeutics has a consensus target price of $24.21, indicating a potential upside of 27.31%. Given MoonLake Immunotherapeutics' stronger consensus rating and higher possible upside, analysts plainly believe MoonLake Immunotherapeutics is more favorable than Neoleukin Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Neoleukin Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 MoonLake Immunotherapeutics 3 Sell rating(s) 4 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.41

Which has higher earnings & valuation, NLTX or MLTX?

Neoleukin Therapeutics is trading at a lower price-to-earnings ratio than MoonLake Immunotherapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Neoleukin Therapeutics N/A N/A -$57.56M -$3.11 N/A MoonLake Immunotherapeutics N/A N/A -$227.32M -$3.87 N/A

Is NLTX or MLTX more profitable?

Neoleukin Therapeutics' return on equity of -37.22% beat MoonLake Immunotherapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Neoleukin Therapeutics N/A -37.22% -30.91% MoonLake Immunotherapeutics N/A -85.15% -60.52%

Do analysts rate XERS or NLTX?

Xeris Biopharma presently has a consensus price target of $10.80, indicating a potential upside of 29.81%. Given Xeris Biopharma's stronger consensus rating and higher probable upside, analysts clearly believe Xeris Biopharma is more favorable than Neoleukin Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Xeris Biopharma 0 Sell rating(s) 3 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.57 Neoleukin Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts rate NLTX or NNNN?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Neoleukin Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Anbio Biotechnology 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has preferable earnings and valuation, NLTX or NNNN?

Anbio Biotechnology has higher revenue and earnings than Neoleukin Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Neoleukin Therapeutics N/A N/A -$57.56M -$3.11 N/A Anbio Biotechnology $8.65M 164.74 $6.40M N/A N/A

Is NLTX or NNNN more profitable?

Anbio Biotechnology's return on equity of 0.00% beat Neoleukin Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Neoleukin Therapeutics N/A -37.22% -30.91% Anbio Biotechnology N/A N/A N/A

Do analysts rate NLTX or INBX?

Inhibrx Biosciences has a consensus price target of $150.00, suggesting a potential upside of 83.94%. Given Inhibrx Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Inhibrx Biosciences is more favorable than Neoleukin Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Neoleukin Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Inhibrx Biosciences 1 Sell rating(s) 3 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.33

Is NLTX or INBX more profitable?

Neoleukin Therapeutics' return on equity of -37.22% beat Inhibrx Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Neoleukin Therapeutics N/A -37.22% -30.91% Inhibrx Biosciences N/A -563.90% -72.32%

Do analysts rate AKTS or NLTX?

Aktis Oncology presently has a consensus price target of $34.60, suggesting a potential upside of 44.83%. Given Aktis Oncology's stronger consensus rating and higher probable upside, equities research analysts plainly believe Aktis Oncology is more favorable than Neoleukin Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aktis Oncology 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.88 Neoleukin Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is AKTS or NLTX more profitable?

Aktis Oncology's return on equity of 0.00% beat Neoleukin Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Aktis Oncology N/A N/A N/A Neoleukin Therapeutics N/A -37.22% -30.91%

Neoleukin Therapeutics (NLTX) Competitors

$34.90 -0.67 (-1.88%)

As of 07/24/2026

Compare

NLTX vs. MLTX, XERS, NNNN, INBX, and AKTS

Should you buy Neoleukin Therapeutics stock or one of its competitors? MarketBeat compares Neoleukin Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Neoleukin Therapeutics include MoonLake Immunotherapeutics (MLTX), Xeris Biopharma (XERS), Anbio Biotechnology (NNNN), Inhibrx Biosciences (INBX), and Aktis Oncology (AKTS). These companies are all part of the "pharmaceutical products" industry.

How does Neoleukin Therapeutics compare to MoonLake Immunotherapeutics?

Neoleukin Therapeutics (NASDAQ:NLTX) and MoonLake Immunotherapeutics (NASDAQ:MLTX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, institutional ownership, profitability, dividends, analyst recommendations, media sentiment and valuation.

Neoleukin Therapeutics has a beta of 1.11, indicating that its share price is 11% more volatile than the broader market. Comparatively, MoonLake Immunotherapeutics has a beta of 1.04, indicating that its share price is 4% more volatile than the broader market.

Neoleukin Therapeutics is trading at a lower price-to-earnings ratio than MoonLake Immunotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neoleukin Therapeutics	N/A	N/A	-$57.56M	-$3.11	N/A
MoonLake Immunotherapeutics	N/A	N/A	-$227.32M	-$3.87	N/A

Neoleukin Therapeutics' return on equity of -37.22% beat MoonLake Immunotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neoleukin Therapeutics	N/A	-37.22%	-30.91%
MoonLake Immunotherapeutics	N/A	-85.15%	-60.52%

MoonLake Immunotherapeutics has a consensus target price of $24.21, indicating a potential upside of 27.31%. Given MoonLake Immunotherapeutics' stronger consensus rating and higher possible upside, analysts plainly believe MoonLake Immunotherapeutics is more favorable than Neoleukin Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neoleukin Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
MoonLake Immunotherapeutics	3 Sell rating(s)	4 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.41

52.4% of Neoleukin Therapeutics shares are owned by institutional investors. Comparatively, 93.8% of MoonLake Immunotherapeutics shares are owned by institutional investors. 1.6% of Neoleukin Therapeutics shares are owned by insiders. Comparatively, 10.4% of MoonLake Immunotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, MoonLake Immunotherapeutics had 15 more articles in the media than Neoleukin Therapeutics. MarketBeat recorded 15 mentions for MoonLake Immunotherapeutics and 0 mentions for Neoleukin Therapeutics. MoonLake Immunotherapeutics' average media sentiment score of 0.74 beat Neoleukin Therapeutics' score of 0.00 indicating that MoonLake Immunotherapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Neoleukin Therapeutics	Neutral
MoonLake Immunotherapeutics	Positive

Summary

MoonLake Immunotherapeutics beats Neoleukin Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Neoleukin Therapeutics compare to Xeris Biopharma?

Xeris Biopharma (NASDAQ:XERS) and Neoleukin Therapeutics (NASDAQ:NLTX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, dividends, analyst recommendations, media sentiment, earnings and profitability.

42.8% of Xeris Biopharma shares are held by institutional investors. Comparatively, 52.4% of Neoleukin Therapeutics shares are held by institutional investors. 4.4% of Xeris Biopharma shares are held by company insiders. Comparatively, 1.6% of Neoleukin Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Xeris Biopharma has a beta of 0.62, meaning that its share price is 38% less volatile than the broader market. Comparatively, Neoleukin Therapeutics has a beta of 1.11, meaning that its share price is 11% more volatile than the broader market.

Xeris Biopharma has a net margin of 3.81% compared to Neoleukin Therapeutics' net margin of 0.00%. Xeris Biopharma's return on equity of 735.00% beat Neoleukin Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xeris Biopharma	3.81%	735.00%	3.24%
Neoleukin Therapeutics	N/A	-37.22%	-30.91%

In the previous week, Xeris Biopharma had 3 more articles in the media than Neoleukin Therapeutics. MarketBeat recorded 3 mentions for Xeris Biopharma and 0 mentions for Neoleukin Therapeutics. Xeris Biopharma's average media sentiment score of 1.64 beat Neoleukin Therapeutics' score of 0.00 indicating that Xeris Biopharma is being referred to more favorably in the media.

Company	Overall Sentiment
Xeris Biopharma	Very Positive
Neoleukin Therapeutics	Neutral

Xeris Biopharma presently has a consensus price target of $10.80, indicating a potential upside of 29.81%. Given Xeris Biopharma's stronger consensus rating and higher probable upside, analysts clearly believe Xeris Biopharma is more favorable than Neoleukin Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xeris Biopharma	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.57
Neoleukin Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Xeris Biopharma has higher revenue and earnings than Neoleukin Therapeutics. Neoleukin Therapeutics is trading at a lower price-to-earnings ratio than Xeris Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xeris Biopharma	$291.85M	4.92	$550K	$0.06	138.67
Neoleukin Therapeutics	N/A	N/A	-$57.56M	-$3.11	N/A

Summary

Xeris Biopharma beats Neoleukin Therapeutics on 13 of the 15 factors compared between the two stocks.

How does Neoleukin Therapeutics compare to Anbio Biotechnology?

Neoleukin Therapeutics (NASDAQ:NLTX) and Anbio Biotechnology (NASDAQ:NNNN) are both small-cap pharmaceutical products companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, earnings, risk, media sentiment, analyst recommendations and institutional ownership.

Neoleukin Therapeutics has a beta of 1.11, suggesting that its stock price is 11% more volatile than the broader market. Comparatively, Anbio Biotechnology has a beta of 5.15, suggesting that its stock price is 415% more volatile than the broader market.

Anbio Biotechnology's return on equity of 0.00% beat Neoleukin Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neoleukin Therapeutics	N/A	-37.22%	-30.91%
Anbio Biotechnology	N/A	N/A	N/A

52.4% of Neoleukin Therapeutics shares are held by institutional investors. 1.6% of Neoleukin Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neoleukin Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Anbio Biotechnology	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Anbio Biotechnology has higher revenue and earnings than Neoleukin Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neoleukin Therapeutics	N/A	N/A	-$57.56M	-$3.11	N/A
Anbio Biotechnology	$8.65M	164.74	$6.40M	N/A	N/A

In the previous week, Anbio Biotechnology had 2 more articles in the media than Neoleukin Therapeutics. MarketBeat recorded 2 mentions for Anbio Biotechnology and 0 mentions for Neoleukin Therapeutics. Anbio Biotechnology's average media sentiment score of 1.43 beat Neoleukin Therapeutics' score of 0.00 indicating that Anbio Biotechnology is being referred to more favorably in the news media.

Company	Overall Sentiment
Neoleukin Therapeutics	Neutral
Anbio Biotechnology	Positive

Summary

Anbio Biotechnology beats Neoleukin Therapeutics on 8 of the 10 factors compared between the two stocks.

How does Neoleukin Therapeutics compare to Inhibrx Biosciences?

Neoleukin Therapeutics (NASDAQ:NLTX) and Inhibrx Biosciences (NASDAQ:INBX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, risk, earnings, dividends, analyst recommendations and institutional ownership.

Neoleukin Therapeutics has higher earnings, but lower revenue than Inhibrx Biosciences. Neoleukin Therapeutics is trading at a lower price-to-earnings ratio than Inhibrx Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neoleukin Therapeutics	N/A	N/A	-$57.56M	-$3.11	N/A
Inhibrx Biosciences	$1.30M	920.32	-$140.05M	-$8.39	N/A

Neoleukin Therapeutics' return on equity of -37.22% beat Inhibrx Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neoleukin Therapeutics	N/A	-37.22%	-30.91%
Inhibrx Biosciences	N/A	-563.90%	-72.32%

Neoleukin Therapeutics has a beta of 1.11, suggesting that its share price is 11% more volatile than the broader market. Comparatively, Inhibrx Biosciences has a beta of 3.41, suggesting that its share price is 241% more volatile than the broader market.

In the previous week, Inhibrx Biosciences had 3 more articles in the media than Neoleukin Therapeutics. MarketBeat recorded 3 mentions for Inhibrx Biosciences and 0 mentions for Neoleukin Therapeutics. Inhibrx Biosciences' average media sentiment score of 0.97 beat Neoleukin Therapeutics' score of 0.00 indicating that Inhibrx Biosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Neoleukin Therapeutics	Neutral
Inhibrx Biosciences	Positive

Inhibrx Biosciences has a consensus price target of $150.00, suggesting a potential upside of 83.94%. Given Inhibrx Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Inhibrx Biosciences is more favorable than Neoleukin Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neoleukin Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Inhibrx Biosciences	1 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.33

52.4% of Neoleukin Therapeutics shares are held by institutional investors. Comparatively, 82.5% of Inhibrx Biosciences shares are held by institutional investors. 1.6% of Neoleukin Therapeutics shares are held by company insiders. Comparatively, 18.3% of Inhibrx Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Inhibrx Biosciences beats Neoleukin Therapeutics on 11 of the 15 factors compared between the two stocks.

How does Neoleukin Therapeutics compare to Aktis Oncology?

Aktis Oncology (NASDAQ:AKTS) and Neoleukin Therapeutics (NASDAQ:NLTX) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, valuation, profitability, media sentiment, dividends, earnings, institutional ownership and risk.

28.8% of Aktis Oncology shares are owned by institutional investors. Comparatively, 52.4% of Neoleukin Therapeutics shares are owned by institutional investors. 3.3% of Aktis Oncology shares are owned by insiders. Comparatively, 1.6% of Neoleukin Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Neoleukin Therapeutics has lower revenue, but higher earnings than Aktis Oncology. Aktis Oncology is trading at a lower price-to-earnings ratio than Neoleukin Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aktis Oncology	$8.28M	154.14	-$63.73M	-$0.38	N/A
Neoleukin Therapeutics	N/A	N/A	-$57.56M	-$3.11	N/A

In the previous week, Aktis Oncology had 5 more articles in the media than Neoleukin Therapeutics. MarketBeat recorded 5 mentions for Aktis Oncology and 0 mentions for Neoleukin Therapeutics. Aktis Oncology's average media sentiment score of 0.66 beat Neoleukin Therapeutics' score of 0.00 indicating that Aktis Oncology is being referred to more favorably in the media.

Company	Overall Sentiment
Aktis Oncology	Positive
Neoleukin Therapeutics	Neutral

Aktis Oncology presently has a consensus price target of $34.60, suggesting a potential upside of 44.83%. Given Aktis Oncology's stronger consensus rating and higher probable upside, equities research analysts plainly believe Aktis Oncology is more favorable than Neoleukin Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aktis Oncology	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Neoleukin Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Aktis Oncology's return on equity of 0.00% beat Neoleukin Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aktis Oncology	N/A	N/A	N/A
Neoleukin Therapeutics	N/A	-37.22%	-30.91%

Summary

Aktis Oncology beats Neoleukin Therapeutics on 11 of the 14 factors compared between the two stocks.

Get Neoleukin Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NLTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NLTX vs. The Competition

Export

Metric	Neoleukin Therapeutics	Pharmaceutical Industry	Medical Sector	NASDAQ Exchange
Market Cap	$327.99M	$975.11M	$6.86B	$12.25B
Dividend Yield	N/A	4.84%	2.67%	9.79%
P/E Ratio	-11.22	1.53	27.14	23.64
Price / Sales	N/A	105.75	517.01	89.03
Price / Cash	N/A	20.06	50.54	59.64
Price / Book	3.15	8.47	10.28	6.07
Net Income	-$57.56M	-$2.70M	$3.60B	$331.99M
7 Day Performance	-6.46%	-2.29%	-1.27%	-0.63%
1 Month Performance	16.06%	-3.97%	-0.37%	-2.00%
1 Year Performance	53.00%	27.39%	18.30%	13.62%

Neoleukin Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NLTX Neoleukin Therapeutics	N/A	$34.90 -1.9%	N/A	+54.0%	$327.99M	N/A	N/A	90	High Trading Volume
MLTX MoonLake Immunotherapeutics	3.1958 of 5 stars	$19.96 +2.3%	$24.21 +21.3%	-65.4%	$1.44B	N/A	N/A	2	Analyst Revision
XERS Xeris Biopharma	3.7087 of 5 stars	$8.70 +5.1%	$10.80 +24.1%	+60.9%	$1.43B	$291.85M	145.00	290	News Coverage Analyst Upgrade
NNNN Anbio Biotechnology	1.4104 of 5 stars	$9.12 -4.1%	N/A	N/A	$1.37B	$8.65M	N/A	27	Positive News Short Interest Decrease
INBX Inhibrx Biosciences	2.9993 of 5 stars	$91.22 -2.1%	$150.00 +64.4%	+253.5%	$1.37B	$1.30M	N/A	166

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NLTX) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Neoleukin Therapeutics (NLTX) Competitors

NLTX vs. MLTX, XERS, NNNN, INBX, and AKTS

How does Neoleukin Therapeutics compare to MoonLake Immunotherapeutics?

Summary

How does Neoleukin Therapeutics compare to Xeris Biopharma?

Summary

How does Neoleukin Therapeutics compare to Anbio Biotechnology?

Summary

How does Neoleukin Therapeutics compare to Inhibrx Biosciences?

Summary

How does Neoleukin Therapeutics compare to Aktis Oncology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NLTX vs. The Competition

Neoleukin Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Neoleukin Therapeutics (NLTX) Competitors

NLTX vs. MLTX, XERS, NNNN, INBX, and AKTS

How does Neoleukin Therapeutics compare to MoonLake Immunotherapeutics?

Which has more volatility and risk, NLTX or MLTX?

Which has higher earnings & valuation, NLTX or MLTX?

Is NLTX or MLTX more profitable?

Do analysts recommend NLTX or MLTX?

Do institutionals and insiders believe in NLTX or MLTX?

Does the media refer more to NLTX or MLTX?

Summary

How does Neoleukin Therapeutics compare to Xeris Biopharma?

Do insiders and institutionals have more ownership in XERS or NLTX?

Which has more risk and volatility, XERS or NLTX?

Is XERS or NLTX more profitable?

Does the media prefer XERS or NLTX?

Do analysts rate XERS or NLTX?

Which has stronger earnings & valuation, XERS or NLTX?

Summary

How does Neoleukin Therapeutics compare to Anbio Biotechnology?

Which has more volatility and risk, NLTX or NNNN?

Is NLTX or NNNN more profitable?

Do insiders & institutionals have more ownership in NLTX or NNNN?

Do analysts rate NLTX or NNNN?

Which has preferable earnings and valuation, NLTX or NNNN?

Does the media favor NLTX or NNNN?

Summary

How does Neoleukin Therapeutics compare to Inhibrx Biosciences?

Which has stronger valuation and earnings, NLTX or INBX?

Is NLTX or INBX more profitable?

Which has more volatility & risk, NLTX or INBX?

Does the media refer more to NLTX or INBX?

Do analysts rate NLTX or INBX?

Do institutionals and insiders have more ownership in NLTX or INBX?

Summary

How does Neoleukin Therapeutics compare to Aktis Oncology?

Do insiders and institutionals hold more shares of AKTS or NLTX?

Which has preferable valuation & earnings, AKTS or NLTX?

Does the media prefer AKTS or NLTX?

Do analysts rate AKTS or NLTX?

Is AKTS or NLTX more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NLTX vs. The Competition

Neoleukin Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools